Gene_name	Ensembl_gene	chr	Gene_old_names	Gene_other_names	Uniprot_acc(HGNC/Uniprot)	Uniprot_id(HGNC/Uniprot)	Entrez_gene_id	CCDS_id	Refseq_id	ucsc_id	MIM_id	OMIM_id	Gene_full_name	Pathway(Uniprot)	Pathway(BioCarta)_short	Pathway(BioCarta)_full	Pathway(ConsensusPathDB)	Pathway(KEGG)_id	Pathway(KEGG)_full	Function_description	Disease_description	MIM_phenotype_id	MIM_disease	Orphanet_disorder_id	Orphanet_disorder	Orphanet_association_type	Trait_association(GWAS)	HPO_id	HPO_name	GO_biological_process	GO_cellular_component	GO_molecular_function	Tissue_specificity(Uniprot)	Expression(egenetics)	Expression(GNF/Atlas)	Interactions(IntAct)	Interactions(BioGRID)	Interactions(ConsensusPathDB)	P(HI)	HIPred_score	HIPred	GHIS	P(rec)	Known_rec_info	RVIS_EVS	RVIS_percentile_EVS	LoF-FDR_ExAC	RVIS_ExAC	RVIS_percentile_ExAC	ExAC_pLI	ExAC_pRec	ExAC_pNull	ExAC_nonTCGA_pLI	ExAC_nonTCGA_pRec	ExAC_nonTCGA_pNull	ExAC_nonpsych_pLI	ExAC_nonpsych_pRec	ExAC_nonpsych_pNull	gnomAD_pLI	gnomAD_pRec	gnomAD_pNull	ExAC_del.score	ExAC_dup.score	ExAC_cnv.score	ExAC_cnv_flag	GDI	GDI-Phred	Gene damage prediction (all disease-causing genes)	Gene damage prediction (all Mendelian disease-causing genes)	Gene damage prediction (Mendelian AD disease-causing genes)	Gene damage prediction (Mendelian AR disease-causing genes)	Gene damage prediction (all PID disease-causing genes)	Gene damage prediction (PID AD disease-causing genes)	Gene damage prediction (PID AR disease-causing genes)	Gene damage prediction (all cancer disease-causing genes)	Gene damage prediction (cancer recessive disease-causing genes)	Gene damage prediction (cancer dominant disease-causing genes)	LoFtool_score	SORVA_LOF_MAF0.005_HetOrHom	SORVA_LOF_MAF0.005_HomOrCompoundHet	SORVA_LOF_MAF0.001_HetOrHom	SORVA_LOF_MAF0.001_HomOrCompoundHet	SORVA_LOForMissense_MAF0.005_HetOrHom	SORVA_LOForMissense_MAF0.005_HomOrCompoundHet	SORVA_LOForMissense_MAF0.001_HetOrHom	SORVA_LOForMissense_MAF0.001_HomOrCompoundHet	Essential_gene	Essential_gene_CRISPR	Essential_gene_CRISPR2	Essential_gene_gene-trap	Gene_indispensability_score	Gene_indispensability_pred	MGI_mouse_gene	MGI_mouse_phenotype	ZFIN_zebrafish_gene	ZFIN_zebrafish_structure	ZFIN_zebrafish_phenotype_quality	ZFIN_zebrafish_phenotype_tag
A1BG	ENSG00000121410	19	.	.	P04217	A1BG_HUMAN	1	CCDS12976	NM_130786	uc002qsd.5	138670	138670	alpha-1-B glycoprotein	.	.	.	Neutrophil degranulation;Innate Immune System;Immune System;Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;Hemostasis	.	.	.	.	.	.	.	.	.	.	.	.	platelet degranulation;biological_process;neutrophil degranulation	extracellular region;extracellular space;platelet alpha granule lumen;secretory granule lumen;collagen-containing extracellular matrix;extracellular exosome;blood microparticle;ficolin-1-rich granule lumen	molecular_function	Plasma.;	lung;thymus;amygdala;spleen;liver;prostate;germinal center;brain;unclassifiable (Anatomical System);islets of Langerhans;	liver;trigeminal ganglion;fetal liver;fetal lung;	9	23	22	0.07384	0.219635888934135	N	0.475182849	0.31615	.	-0.47	23.51	0.8095814	-0.603321593	18.29407867	9.0649236354772e-05	0.786086131023045	0.2138232197406	5.75396312126945e-05	0.695640503723071	0.304301956645716	5.23146388619959e-05	0.645142011091095	0.354805674270043	3.8589e-05	6.2352e-01	3.7644e-01	0.424446392997537	-0.16471566664872	0.0717075961104331	N	79.3774	1.88274	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	8.82E-01	7.987220447284345E-4	0.0	7.987220447284345E-4	0.0	0.032348242811501594	0.0	0.020766773162939296	0.0	.	N	N	N	0.65927761647298	E	A1bg	.	.	.	.	.
A1BG-AS1	ENSG00000268895	19	NCRNA00181;A1BGAS;A1BG-AS	FLJ23569	.	.	503538	.	NR_015380	uc002qse.3	.	.	A1BG antisense RNA 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	7.987220447284345E-4	0.0	7.987220447284345E-4	0.0	0.02875399361022364	0.0	0.017172523961661343	0.0	.	.	.	.	.	.	.	.	.	.	.	.
A1CF	ENSG00000148584	10	.	ACF;ASP;ACF64;ACF65;APOBEC1CF	Q9NQ94	A1CF_HUMAN	29974	CCDS7241;CCDS7242;CCDS7243;CCDS73133	NM_001198818;NM_014576	uc057tgv.1	.	618199	APOBEC1 complementation factor	.	.	.	Metabolism of RNA;Formation of the Editosome;mRNA Editing: C to U Conversion;mRNA Editing	.	.	FUNCTION: Essential component of the apolipoprotein B mRNA editing enzyme complex which is responsible for the postranscriptional editing of a CAA codon for Gln to a UAA codon for stop in APOB mRNA. Binds to APOB mRNA and is probably responsible for docking the catalytic subunit, APOBEC1, to the mRNA to allow it to deaminate its target cytosine. The complex also protects the edited APOB mRNA from nonsense-mediated decay. {ECO:0000269|PubMed:10669759, ECO:0000269|PubMed:10781591, ECO:0000269|PubMed:12881431}.; 	.	.	.	.	.	.	Urate levels in lean individuals[25811787];Urate levels[23263486];Glomerular filtration rate in non diabetics (creatinine)[26831199];Interferon alpha levels in systemic lupus erythematosus[25338677];Narcolepsy with cataplexy[25986216];Glomerular filtration rate (creatinine)[28452372];	.	.	mRNA processing;mRNA localization resulting in posttranscriptional regulation of gene expression;cytidine to uridine editing;mRNA modification;protein stabilization	nucleus;nucleoplasm;cytoplasm;endoplasmic reticulum;apolipoprotein B mRNA editing enzyme complex	RNA binding;double-stranded RNA binding;single-stranded RNA binding;mRNA binding;protein binding	Widely expressed with highest levels in brain, liver, pancreas, colon and spleen. {ECO:0000269|PubMed:10669759}.;	kidney;spleen;liver;colon;stomach;unclassifiable (Anatomical System);islets of Langerhans;	ciliary ganglion;pons;liver;superior cervical ganglion;trigeminal ganglion;atrioventricular node;fetal liver;skeletal muscle;	23	11	28	0.18871	0.65525084733963	Y	0.394639127	0.35999	.	-0.38	28.01	0.009642604	-0.860754331	11.52942594	0.00361970078438154	0.995993655163751	0.000386644051867698	0.00890452958680105	0.990578744051377	0.000516726361822426	0.0395970143112867	0.960063653883332	0.000339331805381442	3.6818e-02	9.3170e-01	3.1479e-02	.	.	.	.	314.85493	3.77246	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	8.77E-01	0.0	0.0	0.0	0.0	0.022763578274760384	0.0	0.0115814696485623	0.0	E	N	N	N	0.542316824803263	E	A1cf	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; 	.	.	.	.
A2M	ENSG00000175899	12	.	FWP007;S863-7;CPAMD5	P01023	A2MG_HUMAN	2	CCDS44827	NM_000014	uc001qvk.2	103950	103950	alpha-2-macroglobulin	.	.	.	Complement and coagulation cascades - Homo sapiens (human);Human Complement System;Dengue-2 Interactions with Complement and Coagulation Cascades;Complement and Coagulation Cascades;Signal Transduction;HDL assembly;Plasma lipoprotein assembly;Extracellular matrix organization;Rho GTPase cycle;Transport of small molecules;Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;Signaling by Rho GTPases;Intrinsic Pathway of Fibrin Clot Formation;Hemostasis;Degradation of the extracellular matrix;Formation of Fibrin Clot (Clotting Cascade);Plasma lipoprotein assembly, remodeling, and clearance;IL6-mediated signaling events	hsa04610;hsa05010	Complement and coagulation cascades;Alzheimer's disease	FUNCTION: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region, a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase.; 	.	.	.	.	.	.	.	HP:0000006;HP:0002185;HP:0002423;HP:0410054;HP:0000726;HP:0001425;HP:0001300;HP:0002511	Autosomal dominant inheritance;Neurofibrillary tangles;Long-tract signs;Decreased level of GABA in serum;Dementia;Heterogeneous;Parkinsonism;Alzheimer disease	negative regulation of complement activation, lectin pathway;platelet degranulation;blood coagulation, intrinsic pathway;negative regulation of endopeptidase activity;extracellular matrix disassembly;positive regulation of GTPase activity;stem cell differentiation;regulation of small GTPase mediated signal transduction	extracellular region;cytosol;platelet alpha granule lumen;collagen-containing extracellular matrix;extracellular exosome;blood microparticle	protease binding;serine-type endopeptidase inhibitor activity;GTPase activator activity;signaling receptor binding;protein binding;growth factor binding;enzyme binding;interleukin-8 binding;interleukin-1 binding;tumor necrosis factor binding;calcium-dependent protein binding	Secreted in plasma. {ECO:0000269|PubMed:6203908}.;	stomach;lacrimal gland;testis;pineal gland;choroid;larynx;kidney;uterus;whole body;pancreas;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;meninges;fovea centralis;pia mater;spleen;liver;gall bladder;heart;dura mater;lung;thyroid;placenta;epididymis;tongue;spinal ganglion;smooth muscle;skin;myocardium;adrenal cortex;unclassifiable (Anatomical System);retina;head and neck;mammary gland;tonsil;hippocampus;endometrium;parathyroid;brain;trabecular meshwork;cerebral cortex;ovary;macula lutea;frontal lobe;colon;prostate;breast;hypothalamus;	.	93	108	256	0.27005	0.318651109933853	N	0.51535125	0.79618	.	0.1	60.76	0.000246125	-0.287657572	31.87759774	0.000540114865271392	0.999459801979781	8.3154947445575e-08	0.000117098127241014	0.999882155833168	7.4603959090444e-07	0.00210877669927573	0.997890874271568	3.49029156306572e-07	1.0438e-02	8.4009e-01	1.4947e-01	1.30395392783652	0.571732419292644	0.944284219107262	N	1920.76046	8.06882	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	9.44E-01	3.9936102236421724E-4	0.0	3.9936102236421724E-4	0.0	0.0694888178913738	0.005591054313099041	0.02915335463258786	3.9936102236421724E-4	.	N	N	N	0.930380431714086	E	A2m	.	.	.	.	.
A2M-AS1	ENSG00000245105	12	.	.	.	.	144571	.	NR_026971	uc009zgj.2	.	618355	A2M antisense RNA 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.	.	.	.	.	.	.	.	.	.	.	.
A2ML1	ENSG00000166535	12	CPAMD9	FLJ25179;p170	A8K2U0	A2ML1_HUMAN	144568	CCDS8596;CCDS73439	NM_001282424;NM_144670	uc001quz.6	610627	610627	alpha-2-macroglobulin like 1	.	.	.	.	.	.	FUNCTION: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase (By similarity). Displays inhibitory activity against chymotrypsin, papain, thermolysin, subtilisin A and, to a lesser extent, elastase but not trypsin. May play an important role during desquamation by inhibiting extracellular proteases. {ECO:0000250|UniProtKB:P01023, ECO:0000269|PubMed:16298998}.; 	.	.	.	648	Noonan syndrome	Disease-causing germline mutation(s) in	Total cholesterol levels[28334899];Small cell lung carcinoma[28604730];Cholesterol, total[24097068];	HP:0000218;HP:0000347;HP:0000465;HP:0001743;HP:0006610;HP:0002650;HP:0000768;HP:0000486;HP:0004415;HP:0000325;HP:0010318;HP:0001260;HP:0002162;HP:0002208;HP:0004209;HP:0007477;HP:0000348;HP:0001252;HP:0000995;HP:0011381;HP:0000474;HP:0002974;HP:0011800;HP:0004322;HP:0100625;HP:0000407;HP:0000179;HP:0001004;HP:0008872;HP:0001641;HP:0000044;HP:0000028;HP:0011869;HP:0002750;HP:0000767;HP:0005692;HP:0001156;HP:0001928;HP:0000391;HP:0000476;HP:0001324;HP:0011675;HP:0000316;HP:0000368;HP:0000639;HP:0000508;HP:0001892;HP:0002240;HP:0000520;HP:0000494;HP:0011362;HP:0000403;HP:0000006;HP:0010982	High palate;Micrognathia;Webbed neck;Abnormality of the spleen;Wide intermamillary distance;Scoliosis;Pectus carinatum;Strabismus;Pulmonary artery stenosis;Triangular face;Aplasia/Hypoplasia of the abdominal wall musculature;Dysarthria;Low posterior hairline;Coarse hair;Clinodactyly of the 5th finger;Abnormal dermatoglyphics;High forehead;Muscular hypotonia;Melanocytic nevus;Aplasia of the semicircular canal;Thickened nuchal skin fold;Radioulnar synostosis;Midface retrusion;Short stature;Enlarged thorax;Sensorineural hearing impairment;Thick lower lip vermilion;Lymphedema;Feeding difficulties in infancy;Abnormal pulmonary valve morphology;Hypogonadotropic hypogonadism;Cryptorchidism;Abnormal platelet function;Delayed skeletal maturation;Pectus excavatum;Joint hyperflexibility;Brachydactyly;Abnormality of coagulation;Thickened helices;Cystic hygroma;Muscle weakness;Arrhythmia;Hypertelorism;Low-set, posteriorly rotated ears;Nystagmus;Ptosis;Abnormal bleeding;Hepatomegaly;Proptosis;Downslanted palpebral fissures;Abnormal hair quantity;Recurrent otitis media;Autosomal dominant inheritance;Polygenic inheritance	negative regulation of endopeptidase activity;regulation of endopeptidase activity	extracellular space;extracellular exosome	serine-type endopeptidase inhibitor activity;peptidase inhibitor activity	In the epidermis, expressed predominantly in the granular layer at the apical edge of keratinocytes (at protein level). Also detected in placenta, testis and thymus but not in epithelia of kidney, lung, small intestine or colon. {ECO:0000269|PubMed:16298998}.;	larynx;frontal lobe;colon;skin;head and neck;hypopharynx;skeletal muscle;breast;unclassifiable (Anatomical System);	ciliary ganglion;pons;tongue;dorsal root ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;globus pallidus;	5	26	279	0.06001	0.145488262176514	N	0.382478725	0.08330	.	2.42	98.53	0.4551833	2.247076871	98.8494669	1.32902210264609e-22	0.201298944611439	0.798701055388561	3.33900304060385e-21	0.189449969718009	0.810550030281991	7.82577911789579e-19	0.499183226011621	0.500816773988379	3.9334e-02	8.4813e-01	1.1254e-01	-2.62354415217069	0.619369230476631	-2.47162789907313	N	7253.67873	18.31932	High	High	High	High	High	High	High	High	High	High	9.60E-01	0.003594249201277955	0.0	0.003594249201277955	0.0	0.10862619808306709	0.010383386581469648	0.050319488817891375	0.003993610223642172	.	N	N	N	0.154649809425639	N	.	.	.	.	.	.
A2ML1-AS1	ENSG00000256661	12	.	.	.	.	100874108	.	.	uc058kxy.1	.	618355	A2ML1 antisense RNA 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.9936102236421724E-4	0.0	3.9936102236421724E-4	0.0	0.01757188498402556	0.0	0.0059904153354632585	0.0	.	.	.	.	.	.	.	.	.	.	.	.
A2ML1-AS2	ENSG00000256904	12	.	.	.	.	106478979	.	.	uc058kyb.1	.	618355	A2ML1 antisense RNA 2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.	.	.	.	.	.	.	.	.	.	.	.
A2MP1	ENSG00000256069	12	A2MP	.	.	.	3	.	NG_001067;NR_040112	.	.	618355	alpha-2-macroglobulin pseudogene 1	.	.	.	.	.	.	.	.	.	.	.	.	.	Depression in smokers[30219690];	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.	.	.	.	.	.	.	.	.	.	.	.
A3GALT2	ENSG00000184389	1	A3GALT2P	IGBS3S;IGB3S	U3KPV4	A3LT2_HUMAN	127550	CCDS60080	NM_001080438	uc031plq.1	.	.	alpha 1,3-galactosyltransferase 2	.	.	.	Glycosphingolipid biosynthesis - globo and isoglobo series - Homo sapiens (human);Ganglio Sphingolipid Metabolism;Globo Sphingolipid Metabolism	.	.	FUNCTION: Synthesizes the galactose-alpha(1,3)-galactose group on the glycosphingolipid isoglobotrihexosylceramide or isogloboside 3 (iGb3) by catalyzing the transfer of galactose from UDP-Galactose to its acceptor molecule Gal-beta-1,4-Glc-ceramide. Can also catalyze the addition of galactose to iGb3 itself to form polygalactose structures. {ECO:0000305|PubMed:23378701}.; 	.	.	.	.	.	.	.	.	.	carbohydrate metabolic process;glycosphingolipid biosynthetic process;lipid glycosylation	Golgi apparatus;integral component of membrane;vesicle;Golgi cisterna membrane	alpha-1,3-galactosyltransferase activity;transferase activity, transferring glycosyl groups;metal ion binding;N-acetyllactosaminide 3-alpha-galactosyltransferase activity	Expressed in thymus and monocyte derived dendritic cells. {ECO:0000269|PubMed:23378701}.;	.	.	1	1	1	0.10629	0.271480917930603	N	.	0.09600	.	.	.	0.9993496	.	.	6.50302639229507e-07	0.145666833765185	0.854332515932176	4.10354185858275e-06	0.216297706724072	0.783698189734069	3.6237402371872e-07	0.0972977463660086	0.902701891259968	1.1526e-07	1.9775e-01	8.0225e-01	-2.62354415217069	0.668347390481294	-2.47162789907313	N	272.82681	3.54057	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	7.987220447284345E-4	0.0	7.987220447284345E-4	0.0	0.0371405750798722	0.0023961661341853034	0.017172523961661343	0.001597444089456869	.	.	.	.	.	.	A3galt2	.	.	.	.	.
A4GALT	ENSG00000128274	22	P1	A14GALT;Gb3S;P(k)	Q9NPC4	A4GAT_HUMAN	53947	CCDS14041	NM_001318038;NM_017436	uc062ewl.1	607922	607922	alpha 1,4-galactosyltransferase (P blood group)	PATHWAY: Protein modification; protein glycosylation.; 	.	.	Glycosphingolipid biosynthesis - globo and isoglobo series - Homo sapiens (human);Glycosphingolipid biosynthesis - lacto and neolacto series - Homo sapiens (human);Globo Sphingolipid Metabolism	hsa00603;hsa01031	Glycosphingolipid biosynthesis - globoseries;Glycan structures - biosynthesis 2	FUNCTION: Necessary for the biosynthesis of the Pk antigen of blood histogroup P. Catalyzes the transfer of galactose to lactosylceramide and galactosylceramide. Necessary for the synthesis of the receptor for bacterial verotoxins.; 	.	111400;	.	.	.	.	Mean platelet volume[27863252];Resting metabolic rate[28476931];Mean corpuscular volume[29403010];Platelet distribution width[27863252];Hematocrit[27863252];Red blood cell count[27863252];Blood protein levels[30072576];Hemoglobin concentration[27863252];Asthma[27611488];	HP:0010970;HP:0000006	Blood group antigen abnormality;Autosomal dominant inheritance	globoside biosynthetic process;protein glycosylation;glycosphingolipid biosynthetic process;plasma membrane organization	membrane;integral component of Golgi membrane	galactosyltransferase activity;toxic substance binding;lactosylceramide 4-alpha-galactosyltransferase activity	Ubiquitous. Highly expressed in kidney, heart, spleen, liver, testis and placenta.;	iris;spleen;liver;cartilage;skin;bone;germinal center;brain;lymphoreticular;unclassifiable (Anatomical System);heart;lung;uterus;whole body;pancreas;bladder;muscle;placenta;prostate;mammary gland;islets of Langerhans;	ciliary ganglion;atrioventricular node;	1	6	6	0.10228	0.241860657930374	N	0.594543329	0.22182	.	-0.29	33.34	0.4309956	-0.397132499	26.39600024	0.111598718084493	0.777534623470403	0.110866658445104	0.0996356613882931	0.77228710762078	0.128077230990927	0.396374656165453	0.555824362996598	0.0478009808379499	7.4990e-06	3.0529e-01	6.9470e-01	-0.0518196231510887	-0.422282930628608	-0.304293379185082	N	67.38232	1.69929	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.009584664536741214	0.0	0.006789137380191693	0.0	N	N	N	N	0.100979845344790	N	A4galt	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype; 	.	.	.	.
A4GNT	ENSG00000118017	3	.	alpha4GnT	Q9UNA3	A4GCT_HUMAN	51146	CCDS3097	NM_016161	uc003ers.2	616709	616709	alpha-1,4-N-acetylglucosaminyltransferase	.	.	.	Post-translational protein modification;Metabolism of proteins;heparan sulfate biosynthesis (late stages);heparan sulfate biosynthesis;O-linked glycosylation of mucins;O-linked glycosylation	hsa01030	Glycan structures - biosynthesis 1	FUNCTION: Catalyzes the transfer of N-acetylglucosamine (GlcNAc) to core 2 branched O-glycans (PubMed:10430883). Necessary for the synthesis of type III mucin which is specifically produced in the stomach, duodenum, and pancreatic duct (PubMed:10430883). May protect against inflammation-associated gastric adenocarcinomas (By similarity). {ECO:0000250|UniProtKB:Q14BT6, ECO:0000269|PubMed:10430883}.; 	.	.	.	.	.	.	.	.	.	carbohydrate metabolic process;protein O-linked glycosylation;glycoprotein biosynthetic process;O-glycan processing;negative regulation of epithelial cell proliferation	Golgi membrane;membrane;integral component of membrane	acetylglucosaminyltransferase activity	Detected in stomach and pancreas. {ECO:0000269|PubMed:10430883}.;	kidney;stomach;	ciliary ganglion;subthalamic nucleus;dorsal root ganglion;skin;superior cervical ganglion;cingulate cortex;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;	1	20	20	0.08072	0.220953673124313	N	.	0.08845	.	1.11	92.04	0.03822979	0.77157798	86.60924041	0.598408702159303	0.392305268458394	0.00928602938230314	0.556812667378603	0.430313484547724	0.0128738480736728	0.566348207682024	0.419243992148573	0.0144078001694026	1.7010e-01	8.1734e-01	1.2563e-02	0.47610366952285	-0.22065786461885	0.0598329813116912	N	233.66	3.30331	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	2.60E-01	0.0027955271565495207	0.0	0.0	0.0	0.02875399361022364	0.0011980830670926517	0.010782747603833865	3.9936102236421724E-4	.	N	N	N	0.148436449587239	N	A4gnt	cellular phenotype; neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); digestive/alimentary phenotype; immune system phenotype; 	.	.	.	.
AAAS	ENSG00000094914	12	.	.	Q9NRG9	AAAS_HUMAN	8086	CCDS8856;CCDS53797	NM_001173466	uc001scr.5	605378	605378	aladin WD repeat nucleoporin	.	.	.	RNA transport - Homo sapiens (human);tRNA processing;Disease;Gene expression (Transcription);Regulation of HSF1-mediated heat shock response;Metabolism of carbohydrates;Rev-mediated nuclear export of HIV RNA;Late Phase of HIV Life Cycle;HIV Life Cycle;Interactions of Rev with host cellular proteins;Host Interactions of HIV factors;HIV Infection;snRNP Assembly;Vpr-mediated nuclear import of PICs;SUMOylation of DNA damage response and repair proteins;Transport of Ribonucleoproteins into the Host Nucleus;Viral Messenger RNA Synthesis;Export of Viral Ribonucleoproteins from Nucleus;SUMOylation of chromatin organization proteins;Influenza Viral RNA Transcription and Replication;Cellular responses to stress;SUMOylation of RNA binding proteins;Post-translational protein modification;SUMOylation of DNA replication proteins;SUMO E3 ligases SUMOylate target proteins;NEP/NS2 Interacts with the Cellular Export Machinery;Metabolism of proteins;Influenza Life Cycle;Influenza Infection;Metabolism of RNA;Infectious disease;Metabolism;Transport of the SLBP independent Mature mRNA;Transport of the SLBP Dependant Mature mRNA;Transport of Mature mRNA Derived from an Intronless Transcript;Transport of Mature mRNAs Derived from Intronless Transcripts;SUMOylation;Cellular responses to external stimuli;Regulation of Glucokinase by Glucokinase Regulatory Protein;Glycolysis;Nuclear Pore Complex (NPC) Disassembly;tRNA processing in the nucleus;Transport of Mature mRNA derived from an Intron-Containing Transcript;Metabolism of non-coding RNA;Cellular response to heat stress;Nuclear Envelope Breakdown;Mitotic Prophase;M Phase;Nuclear import of Rev protein;Glucose metabolism;Transcriptional regulation by small RNAs;Cell Cycle;Interactions of Vpr with host cellular proteins;Cell Cycle, Mitotic;Transport of Mature Transcript to Cytoplasm;Processing of Capped Intron-Containing Pre-mRNA;Gene Silencing by RNA	.	.	FUNCTION: Plays a role in the normal development of the peripheral and central nervous system.; 	.	231550;	.	869	Triple A syndrome	Disease-causing germline mutation(s) in	.	HP:0007440;HP:0000505;HP:0001250;HP:0001761;HP:0007556;HP:0000982;HP:0002093;HP:0010486;HP:0000846;HP:0000830;HP:0001251;HP:0001252;HP:0004322;HP:0001430;HP:0007002;HP:0002376;HP:0000648;HP:0002571;HP:0000407;HP:0001347;HP:0000252;HP:0000612;HP:0009916;HP:0000252;HP:0011463;HP:0003487;HP:0008163;HP:0001347;HP:0007002;HP:0002571;HP:0001260;HP:0003676;HP:0001324;HP:0000648;HP:0001278;HP:0000649;HP:0012332;HP:0001249;HP:0000972;HP:0008259;HP:0000522;HP:0000522;HP:0004322;HP:0000007;HP:0001263;HP:0004319;HP:0001251;HP:0000953	Generalized hyperpigmentation;Visual impairment;Seizure;Pes cavus;Plantar hyperkeratosis;Palmoplantar keratoderma;Respiratory insufficiency;Abnormality of the hypothenar eminence;Adrenal insufficiency;Anterior hypopituitarism;Ataxia;Muscular hypotonia;Short stature;Abnormality of the calf musculature;Motor axonal neuropathy;Developmental regression;Optic atrophy;Achalasia;Sensorineural hearing impairment;Hyperreflexia;Microcephaly;Iris coloboma;Anisocoria;Microcephaly;Childhood onset;Babinski sign;Decreased circulating cortisol level;Hyperreflexia;Motor axonal neuropathy;Achalasia;Dysarthria;Progressive;Muscle weakness;Optic atrophy;Orthostatic hypotension;Abnormality of visual evoked potentials;Abnormal autonomic nervous system physiology;Intellectual disability;Palmoplantar hyperkeratosis;Adrenocorticotropin receptor defect;Alacrima;Alacrima;Short stature;Autosomal recessive inheritance;Global developmental delay;Decreased circulating aldosterone level;Ataxia;Hyperpigmentation of the skin	mRNA export from nucleus;nucleocytoplasmic transport;learning;fertilization;viral process;regulation of nucleocytoplasmic transport	nucleus;nuclear envelope;nuclear pore;nucleoplasm;centrosome;cytosol;membrane;nuclear membrane	molecular_function	Widely expressed (PubMed:11159947, PubMed:16022285). Particularly abundant in cerebellum, corpus callosum, adrenal gland, pituitary gland, gastrointestinal structures and fetal lung (PubMed:11159947). {ECO:0000269|PubMed:11159947, ECO:0000269|PubMed:16022285}.;	thymus;epididymis;spinal ganglion;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;whole body;retina;pancreas;mammary gland;trophoblast;skeletal muscle;islets of Langerhans;visual apparatus;cervix;iris;hippocampus;spleen;liver;cartilage;endometrium;bone;germinal center;brain;blood;heart;bone marrow;lung;ovary;bladder;colon;placenta;prostate;nasopharynx;breast;hypothalamus;medulla oblongata;amnion;	.	14	25	2089	0.60947	0.26556670665741	N	0.609295536	.	.	-0.91	9.96	0.2678406	-0.238434388	34.73887115	4.54287182926272e-10	0.792914348866523	0.20708565067919	5.82966704896718e-09	0.847767027247157	0.152232966923176	9.30725395497456e-11	0.43383030274595	0.566169697160977	3.0735e-12	2.7025e-01	7.2975e-01	-0.0332104949181626	-0.834987294710156	-0.554664506697577	N	101.66522	2.18230	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	1.78E-01	0.0023961661341853034	0.0	0.0023961661341853034	0.0	0.017172523961661343	0.0	0.0115814696485623	0.0	N	N	N	N	0.537758866542784	E	Aaas	reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); growth/size/body region phenotype; 	.	.	.	.
AACS	ENSG00000081760	12	.	FLJ12389;SUR-5;ACSF1	Q86V21	AACS_HUMAN	65985	CCDS9263	NM_001319839;NM_023928	uc001uhc.4	614364	614364	acetoacetyl-CoA synthetase	.	.	.	Butanoate metabolism - Homo sapiens (human);Valine, leucine and isoleucine degradation - Homo sapiens (human);Butanoate metabolism;Metabolism of lipids;Metabolism;Synthesis of Ketone Bodies;Ketone body metabolism	hsa00650	Butanoate metabolism	FUNCTION: Activates acetoacetate to acetoacetyl-CoA. May be involved in utilizing ketone body for the fatty acid-synthesis during adipose tissue development (By similarity). {ECO:0000250}.; 	.	.	.	.	.	.	.	.	.	liver development;fatty acid metabolic process;response to nutrient;response to purine-containing compound;positive regulation of insulin secretion;response to oleic acid;response to starvation;response to ethanol;ketone body biosynthetic process;white fat cell differentiation;adipose tissue development;cellular response to glucose stimulus;cellular response to testosterone stimulus;cellular response to cholesterol	cytosol	protein binding;ATP binding;acetoacetate-CoA ligase activity;butyrate-CoA ligase activity	Highly expressed in kidney, heart and brain, but low in liver. {ECO:0000269|PubMed:12623130}.;	intestine;pharynx;epididymis;cornea;alveolus;skin;stomach;lacrimal gland;testis;pituitary gland;lymphoreticular;unclassifiable (Anatomical System);kidney;uterus;muscle;bile duct;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;spleen;liver;cartilage;parathyroid;brain;blood;bone marrow;lung;salivary gland;ovary;thyroid;frontal lobe;colon;placenta;prostate;nasopharynx;optic nerve;hypothalamus;	amygdala;temporal lobe;prefrontal cortex;whole brain;cingulate cortex;adipose tissue;parietal lobe;testis;	1	6	6	0.18243	0.389227211475372	N	0.535377068	0.23898	.	-1.17	6.04	0.8807252	0.991830136	90.9041624	4.2456926056096e-12	0.17179010103688	0.828209898958874	9.11829535385171e-12	0.142053059913501	0.85794694007738	5.35345111272765e-12	0.097587256682326	0.902412743312321	6.6538e-08	1.4671e-01	8.5329e-01	0.607059386287841	0.990132030567623	0.999713055858048	N	163.63033	2.79374	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	8.87E-01	7.987220447284345E-4	0.0	7.987220447284345E-4	0.0	0.0231629392971246	0.0	0.019169329073482427	0.0	.	N	N	N	0.779725884789571	E	Aacs	.	.	.	.	.
AACSP1	ENSG00000250420	5	AACSL	.	.	.	729522	.	NR_024035	.	.	618355	acetoacetyl-CoA synthetase pseudogene 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.	.	.	.	.	.	.	.	.	.	.	.
AADAC	ENSG00000114771	3	.	DAC;CES5A1	P22760	AAAD_HUMAN	13	CCDS33877	NM_001086	uc003eze.4	600338	600338	arylacetamide deacetylase	.	.	.	Phase I - Functionalization of compounds;Biological oxidations;Metabolism	hsa00960	Alkaloid biosynthesis II	FUNCTION: Displays cellular triglyceride lipase activity in liver, increases the levels of intracellular fatty acids derived from the hydrolysis of newly formed triglyceride stores and plays a role in very low-density lipoprotein assembly. Displays serine esterase activity in liver. Deacetylates a variety of arylacetamide substrates, including xenobiotic compounds and procarcinogens, converting them to the primary arylamide compounds and increasing their toxicity. {ECO:0000269|PubMed:17936933, ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:23542347}.; 	.	.	.	.	.	.	Male-pattern baldness[29146897];Immunoglobulin A[20694011];	.	.	xenobiotic metabolic process;positive regulation of triglyceride catabolic process	endoplasmic reticulum membrane;integral component of membrane;organelle membrane	catalytic activity;triglyceride lipase activity;lipase activity;serine hydrolase activity;deacetylase activity	Detected in liver (at protein level). Mainly expressed in liver, small intestine, colon, adrenal gland and bladder. {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931}.;	spleen;liver;stomach;testis;parathyroid;unclassifiable (Anatomical System);heart;lung;kidney;ovary;uterus;pancreas;colon;placenta;small intestine;adrenal gland;skeletal muscle;	temporal lobe;liver;superior cervical ganglion;cingulate cortex;adrenal gland;fetal lung;fetal liver;parietal lobe;adrenal cortex;skeletal muscle;	1	1	1	0.02400	0.146139457821846	N	0.45851715	0.07726	.	-0.09	46.92	0.4790128	0.424643567	75.17017047	0.000181834436419695	0.703259060740575	0.296559104823006	0.000123017333186399	0.619307498886139	0.380569483780675	0.000114326357850983	0.572775235666846	0.427110437975303	6.5242e-03	7.6204e-01	2.3144e-01	.	.	.	.	98.58087	2.14611	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	8.19E-01	0.0	0.0	0.0	0.0	0.01757188498402556	0.0	0.015175718849840255	0.0	.	N	N	N	0.672806845631442	E	Aadac	.	.	.	.	.
AADACL2	ENSG00000197953	3	.	MGC72001	Q6P093	ADCL2_HUMAN	344752	CCDS3161	NM_207365	uc003ezc.4	.	618355	arylacetamide deacetylase like 2	.	.	.	.	.	.	.	.	.	.	.	.	.	Breast cancer and/or colorectal cancer[29698419];	.	.	.	extracellular region;integral component of membrane	carboxylic ester hydrolase activity	.	lung;uterus;colon;placenta;heart;	.	1	1	1	0.06376	0.24753013253212	N	0.571717555	0.11585	.	-0.31	31.93	0.4652944	0.498370563	78.15191856	1.78138870795841e-08	0.230782215605282	0.769217766580831	4.55103650326306e-06	0.628415395539015	0.371580053424482	5.8508584730572e-08	0.223401120213718	0.776598821277697	1.0332e-08	9.6542e-02	9.0346e-01	.	.	.	.	62.30478	1.61119	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	8.78E-01	0.001597444089456869	0.0	0.001597444089456869	0.0	0.0231629392971246	0.0	0.014776357827476038	0.0	.	N	N	N	0.186706125116387	N	Aadacl2	.	.	.	.	.
AADACL2-AS1	ENSG00000242908	3	.	.	.	.	101928142	.	NR_110202	.	.	618355	AADACL2 antisense RNA 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0011980830670926517	0.0	0.0011980830670926517	0.0	0.03394568690095846	3.9936102236421724E-4	0.027156549520766772	3.9936102236421724E-4	.	.	.	.	.	.	.	.	.	.	.	.
AADACL3	ENSG00000188984	1	.	OTTHUMG00000001887	Q5VUY0	ADCL3_HUMAN	126767	CCDS41253	NM_001103170	uc057ckc.1	.	618355	arylacetamide deacetylase like 3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	integral component of membrane	carboxylic ester hydrolase activity	.	.	.	1	1	1	0.07474	0.111908376216888	N	.	0.07813	.	2.13	97.92	0.7786481	0.870145349	88.77778447	0.00015633351437561	0.43495652549271	0.564887140992915	0.000117144409649473	0.381194522077175	0.618688333513175	0.000110836921442839	0.347331669753516	0.652557493325041	1.3173e-02	6.7569e-01	3.1114e-01	-0.0099947629380129	-2.53125239294469	-2.47162789907313	N	843.85416	5.68691	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	9.20E-01	3.9936102236421724E-4	0.0	3.9936102236421724E-4	0.0	0.03194888178913738	0.003594249201277955	0.015175718849840255	3.9936102236421724E-4	.	N	N	N	0.070422688089105	N	Aadacl3	.	.	.	.	.
AADACL4	ENSG00000204518	1	.	OTTHUMG00000001889	Q5VUY2	ADCL4_HUMAN	343066	CCDS30590	NM_001013630	uc001auf.3	.	618355	arylacetamide deacetylase like 4	.	.	.	.	.	.	.	.	.	.	.	.	.	Obesity-related traits[23251661];	.	.	.	integral component of membrane	carboxylic ester hydrolase activity	.	.	.	1	1	1	0.05904	0.111908376216888	N	0.426778283	0.09282	.	-0.62	17.32	0.438909	0.088963968	56.58092886	0.000547686324044419	0.700937101417738	0.298515212258218	0.000396274565193363	0.63165668793443	0.367947037500376	0.000377692943043426	0.590622287326069	0.409000019730887	1.7273e-04	4.6811e-01	5.3171e-01	1.11523579451166	-2.53125239294469	-2.47162789907313	N	51.31876	1.41305	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	7.87E-01	0.0011980830670926517	0.0	0.0011980830670926517	0.0	0.03035143769968051	3.9936102236421724E-4	0.022364217252396165	3.9936102236421724E-4	.	N	N	N	0.327168817346435	N	Aadacl4	.	.	.	.	.
AADACP1	ENSG00000240602	3	.	.	.	.	201651	.	NR_026915	.	.	618355	arylacetamide deacetylase pseudogene 1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	.	.	.	.	.	.	.	.	.	.	.	.
AADAT	ENSG00000109576	4	.	KATII;KAT2;KYAT2	Q8N5Z0	AADAT_HUMAN	51166	CCDS3814;CCDS75209	NM_016228;NM_001286682	uc032udw.1	611754	611754	aminoadipate aminotransferase	PATHWAY: Amino-acid degradation; L-lysine degradation via saccharopine pathway; glutaryl-CoA from L-lysine: step 4/6.; 	.	.	Tryptophan metabolism - Homo sapiens (human);Lysine degradation - Homo sapiens (human);Lysine Degradation;Hyperlysinemia I, Familial;2-aminoadipic 2-oxoadipic aciduria;Pyridoxine dependency with seizures;Saccharopinuria/Hyperlysinemia II;Tryptophan Metabolism;Glutaric Aciduria Type I;Hyperlysinemia II or Saccharopinuria;Tryptophan metabolism;Lysine catabolism;Tryptophan catabolism;Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism;Metabolism of amino acids and derivatives;Metabolism;Lysine degradation;L-kynurenine degradation;Lysine metabolism;Tryptophan metabolism;Butanoate metabolism;lysine degradation II (pipecolate pathway);lysine degradation I (saccharopine pathway)	hsa00300;hsa00310;hsa00380	Lysine biosynthesis;Lysine degradation;Tryptophan metabolism	FUNCTION: Transaminase with broad substrate specificity. Has transaminase activity towards aminoadipate, kynurenine, methionine and glutamate. Shows activity also towards tryptophan, aspartate and hydroxykynurenine. Accepts a variety of oxo-acids as amino- group acceptors, with a preference for 2-oxoglutarate, 2- oxocaproic acid, phenylpyruvate and alpha-oxo-gamma-methiol butyric acid. Can also use glyoxylate as amino-group acceptor (in vitro). {ECO:0000269|PubMed:18620547}.; 	.	.	.	.	.	.	Thyroid hormone levels[23408906;23408906];	.	.	2-oxoglutarate metabolic process;glutamate metabolic process;lysine catabolic process;tryptophan catabolic process;biosynthetic process;L-lysine catabolic process to acetyl-CoA via saccharopine;kynurenine metabolic process;L-kynurenine metabolic process;alpha-amino acid metabolic process	mitochondrial matrix	transaminase activity;kynurenine-oxoglutarate transaminase activity;pyridoxal phosphate binding;protein homodimerization activity;2-aminoadipate transaminase activity	Higher expression in the liver. Also found in heart, brain, kidney, pancreas, prostate, testis and ovary.;	cochlea;spleen;liver;endometrium;skin;stomach;bone;lacrimal gland;testis;parathyroid;brain;unclassifiable (Anatomical System);lung;ovary;whole body;retina;lymph node;colon;placenta;prostate;mammary gland;islets of Langerhans;visual apparatus;	trigeminal ganglion;	1	2	1	0.07259	0.625439941883087	Y	0.476627194	0.12828	.	-0.12	44.89	0.2884422	-0.509129461	21.33606409	0.250802295313827	0.747906651301809	0.0012910533843643	0.176181534881784	0.821132511838112	0.00268595328010404	0.507704650145053	0.491279852410939	0.00101549744400798	1.4714e-01	8.5272e-01	1.4210e-04	-0.742674441522589	0.843462931794366	0.212265084714919	N	7.64128	0.28257	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	3.26E-01	0.0	0.0	0.0	0.0	0.00439297124600639	0.0	0.00439297124600639	0.0	N	N	N	N	0.994750614986312	E	Aadat	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; 	.	.	.	.
AAGAB	ENSG00000103591	15	.	FLJ11506;p34	Q6PD74	AAGAB_HUMAN	79719	CCDS42050;CCDS61679	NM_001271885;NM_024666	uc002aqk.6	614888	614888	alpha and gamma adaptin binding protein	.	.	.	.	.	.	FUNCTION: May be involved in endocytic recycling of growth factor receptors such as EGFR. {ECO:0000269|PubMed:23064416}.; 	.	148600;	.	79501	Punctate palmoplantar keratoderma type 1	Disease-causing germline mutation(s) (loss of function) in	Allergic rhinitis[30013184];Asthma[29273806;29273806];	HP:0003002;HP:0003003;HP:0005584;HP:0012189;HP:0001597;HP:0000982;HP:0006740;HP:0002894;HP:0025092;HP:0000006;HP:0001425;HP:0040162;HP:0007530;HP:0025114;HP:0003584;HP:0007530	Breast carcinoma;Colon cancer;Renal cell carcinoma;Hodgkin lymphoma;Abnormality of the nail;Palmoplantar keratoderma;Transitional cell carcinoma of the bladder;Neoplasm of the pancreas;Epidermal acanthosis;Autosomal dominant inheritance;Heterogeneous;Orthokeratosis;Punctate palmoplantar hyperkeratosis;Hypergranulosis;Late onset;Punctate palmoplantar hyperkeratosis	protein transport	cytoplasm;cytosol;nuclear speck	protein binding	Widely expressed, including in skin and keratinocytes, with highest levels in adrenal gland, rectum and thymus. {ECO:0000269|PubMed:23000146, ECO:0000269|PubMed:23064416}.;	skin;stomach;testis;pituitary gland;lens;pineal gland;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;whole body;retina;pancreas;head and neck;mammary gland;islets of Langerhans;visual apparatus;epidermis;fovea centralis;iris;vein;hippocampus;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;duodenum;trabecular meshwork;lung;ovary;macula lutea;frontal lobe;colon;placenta;nasopharynx;optic nerve;medulla oblongata;	ciliary ganglion;cingulate cortex;superior cervical ganglion;atrioventricular node;trigeminal ganglion;parietal lobe;skeletal muscle;	8	22	597	.	0.320778280496597	N	0.552042736	.	.	0.02	55.61	0.02228274	0.008523594	50.96680923	0.00810207313151983	0.977864167974257	0.0140337588942233	0.0274232332373609	0.961053826394535	0.0115229403681042	0.12255249954075	0.871065809991603	0.00638169046764781	9.2627e-08	3.1412e-01	6.8588e-01	1.69832490195333	1.1829529562418	1.53565760833972	N	3541.69204	11.48310	Medium	Medium	Medium	Medium	Medium	High	Medium	Medium	Medium	Medium	7.51E-01	0.0	0.0	0.0	0.0	0.018370607028753993	3.9936102236421724E-4	0.009185303514376996	3.9936102236421724E-4	.	N	N	N	0.965117617036297	E	Aagab	.	.	.	.	.
AAK1	ENSG00000115977	2	.	KIAA1048;DKFZp686K16132	Q2M2I8	AAK1_HUMAN	22848	CCDS1893	NM_014911	uc002sfp.3	616405	616405	AP2 associated kinase 1	.	.	.	Vesicle-mediated transport;Membrane Trafficking;Clathrin-mediated endocytosis;Cargo recognition for clathrin-mediated endocytosis	.	.	FUNCTION: Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis. Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1. Regulates phosphorylation of other AP-2 subunits as well as AP-2 localization and AP-2-mediated internalization of ligand complexes. Phosphorylates NUMB and regulates its cellular localization, promoting NUMB localization to endosomes. Binds to and stabilizes the activated form of NOTCH1, increases its localization in endosomes and regulates its transcriptional activity. {ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:17494869, ECO:0000269|PubMed:18657069, ECO:0000269|PubMed:21464124}.; 	.	.	.	.	.	.	Serum thyroid-stimulating hormone levels[25436638];Parkinson's disease (age of onset)[19772629];Metabolite levels (Dihydroxy docosatrienoic acid)[23934736];	.	.	protein phosphorylation;endocytosis;regulation of endocytosis;regulation of protein localization;positive regulation of Notch signaling pathway;protein autophosphorylation;protein stabilization;membrane organization;regulation of clathrin-dependent endocytosis	nucleus;cytosol;clathrin-coated pit;extrinsic component of plasma membrane;clathrin-coated vesicle;cell leading edge;terminal bouton	protein serine/threonine kinase activity;Notch binding;protein binding;ATP binding;AP-2 adaptor complex binding	Detected in brain, heart and liver. Isoform 1 is the predominant isoform in brain. {ECO:0000269|PubMed:17494869}.;	.	.	25	32	1079	0.09908	0.710111796855927	Y	0.540649852	0.09543	.	-0.66	15.91	5.95412E-06	-0.406975252	25.82976929	0.99932042127733	0.000679578553667441	1.69002206897236e-10	0.998399178233636	0.00160082040499888	1.36136535975836e-09	0.99806251657305	0.0019374807775396	2.64941021975964e-09	1.0000e+00	6.0554e-07	5.7034e-18	0.793079807370152	-0.362979294295052	0.0165679720375777	N	3996.40242	12.50722	Medium	Medium	Medium	Medium	High	High	Medium	High	Medium	High	.	0.0	0.0	0.0	0.0	0.027156549520766772	0.0011980830670926517	0.015175718849840255	0.0011980830670926517	.	N	S	N	0.446128515592442	N	Aak1	hearing/vestibular/ear phenotype; 	.	.	.	.
AAMDC	ENSG00000087884	11	C11orf67	PTD015;FLJ21035;CK067	Q9H7C9	AAMDC_HUMAN	28971	CCDS8254;CCDS81604;CCDS81605;CCDS86232	NM_024684;NM_001316957	uc058fuq.1	.	.	adipogenesis associated Mth938 domain containing	.	.	.	.	.	.	FUNCTION: May play a role in preadipocyte differentiation and adipogenesis. {ECO:0000250}.; 	.	.	.	.	.	.	.	.	.	positive regulation of fat cell differentiation	cytoplasm	protein binding	.	.	.	4	6	7	0.07691	0.51374340057373	Y	0.498742885	0.11262	.	0.28	71.08	0.7289784	0.09443972	56.9122342	0.000474346768584031	0.434325570839455	0.565200082391962	0.000385379687432095	0.395302469716538	0.60431215059603	0.0197063651142291	0.713105358812148	0.267188276073623	2.5621e-05	3.2335e-01	6.7663e-01	.	.	.	.	1406.35943	7.00705	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	7.987220447284345E-4	0.0	7.987220447284345E-4	0.0	0.011980830670926517	0.0	0.011980830670926517	0.0	.	N	N	N	.	.	Aamdc	.	.	.	.	.
AAMP	ENSG00000127837	2	.	.	Q13685	AAMP_HUMAN	14	CCDS33378;CCDS77530	NM_001087	uc002vhk.4	603488	603488	angio associated migratory cell protein	.	.	.	Nucleotide-binding Oligomerization Domain (NOD) pathway	.	.	FUNCTION: Plays a role in angiogenesis and cell migration. In smooth muscle cell migration, may act through the RhoA pathway. {ECO:0000269|PubMed:10329261, ECO:0000269|PubMed:18634987}.; 	.	.	.	.	.	.	Inflammatory bowel disease[28067908];Smooth-surface caries[23470693];Ulcerative colitis[21297633];	.	.	angiogenesis;positive regulation of endothelial cell migration;smooth muscle cell migration;cell differentiation;ribosomal large subunit biogenesis	cytosol;plasma membrane;cell surface;microtubule cytoskeleton;intercellular bridge	heparin binding;unfolded protein binding	Expressed in metastatic melanoma, liver, skin, kidney, heart, lung, lymph node, skeletal muscle and brain, and also in A2058 melanoma cells and activated T-cells (at protein level). Expressed in blood vessels. Strongly expressed in endothelial cells, cytotrophoblasts, and poorly differentiated. colon adenocarcinoma cells found in lymphatics. {ECO:0000269|PubMed:10329261, ECO:0000269|PubMed:7743515}.;	stomach;lacrimal gland;testis;choroid;larynx;kidney;uterus;whole body;pancreas;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;iris;vein;spleen;liver;peripheral nerve;germinal center;heart;lung;synovium;thyroid;sympathetic chain;placenta;optic nerve;thymus;alveolus;skin;pituitary gland;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);cerebellum;retina;muscle;head and neck;mammary gland;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;duodenum;cerebral cortex;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;prostate;breast;hypothalamus;medulla oblongata;	pons;superior cervical ganglion;	13	33	50	0.49551	0.728293240070343	Y	0.568337487	0.12230	.	0.04	57.15	0.1158129	-0.201409962	36.82910668	0.531201269396819	0.468105024546197	0.000693706056983601	0.428698721018279	0.569781001396053	0.00152027758566808	0.786425030259308	0.213224423570513	0.000350546170179032	8.4334e-01	1.5612e-01	5.4615e-04	-0.0817346350247243	-0.0550237015673831	-0.0508828398282936	N	343.13644	3.92709	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	5.36E-01	0.0	0.0	0.0	0.0	0.019169329073482427	3.9936102236421724E-4	0.009584664536741214	0.0	.	E	E	E	0.628152374341873	E	Aamp	.	.	.	.	.
